Karyopharm bags an up­set win at the FDA as reg­u­la­tors OK myelo­ma drug de­spite a host of ob­jec­tions

6 years ago
R&D

Do ex­ec de­par­tures por­tend clin­i­cal dis­as­ters? An­a­lyst counts the ex­am­ples

6 years ago
R&D

Gold­man Sach­s' Ankang Li heads to biotech Terns as new CFO; SV re­cruits new part­ner for De­men­tia Dis­cov­ery Fund

6 years ago
Peer Review

GSK's Dova­to wins EU ap­proval; Red­Hill se­cures speedy re­view for H. py­lori drug

6 years ago
News Briefing

Epi­der­mol­y­sis bul­losa: FDA seeks to help de­vel­op­ment of new treat­ments

6 years ago
FDA+

Go­ing for it: GSK’s Hal Bar­ron out­lines a big PhI­II pro­gram for rheuma­toid arthri­tis — go­ing head-to-head with ...

6 years ago
People
R&D

Boston Bio­med­ical's lead drug fiz­zles in dif­fi­cult-to-treat pan­cre­at­ic can­cer

6 years ago
R&D

Just how much would no-deal Brex­it harm bio­med­ical sci­ence? Re­searchers speak out

6 years ago
R&D
Discovery

Roche’s new flu drug con­tin­ues to rack up PhI­II suc­cess­es — but can it beat gener­ic Tam­i­flu with out­comes like ...

6 years ago
R&D

Five US states agree to sus­pend lit­i­ga­tion against bank­rupt opi­oid mak­er In­sys — re­port

6 years ago
FDA+

Unum shares ric­o­chet low­er as pre­mier drug slams in­to its sec­ond safe­ty cri­sis, FDA slaps an­oth­er hold on PhI

6 years ago
R&D

Got­tlieb re­buts Sci­ence re­port on plum­met­ing FDA in­spec­tions; Lib­tayo wins EMA and NICE en­dorse­ment

6 years ago
News Briefing

In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

6 years ago
Deals
China

Ex-FDA com­mish Scott Got­tlieb says he's 'very proud' of Pfiz­er post as top Dem at­tacks in­flu­ence ped­dling

6 years ago
People

Em­bold­ened by AS­CO da­ta, FDA etch­es speedy ap­proval path for Io­vance's cer­vi­cal can­cer ther­a­py

6 years ago
FDA+

Bio­gen arms it­self with im­pres­sive dura­bil­i­ty stats on Spin­raza as No­var­tis’ ri­val gene ther­a­py takes the field

6 years ago
R&D

Boehringer builds out NASH pipeline with up to $870M deal with South Ko­re­a's Yuhan

6 years ago
Deals

SV joins CRUK on a $250M-plus fund with an eye on de­vel­op­ing new can­cer drugs

6 years ago
Financing

Watch out Ab­b­Vie: Gilead is fast on your heels at the FDA with ri­val JAK in­hibitor fil­go­tinib

6 years ago
R&D
FDA+

Bull­ish Amarin dou­bling sales force in fast run-up to the big FDA de­ci­sion on Vas­cepa

6 years ago
R&D
FDA+

Mer­ri­mack CEO, CFO bow out, months af­ter last clin­i­cal drug fiz­zles

6 years ago
People

In­vestors trapped for an­oth­er 28 days as sus­pen­sion of Wood­ford flag­ship fund drags on

6 years ago
People
Financing

Bay­er, Ver­sant back a $250M cell ther­a­py start­up on a quest to cre­ate off-the-shelf im­muno-on­col­o­gy ther­a­pies

6 years ago
Financing
Cell/Gene Tx

Neil Wood­ford re­fresh­es port­fo­lio with fire sale while in­vestors pon­der fu­ture of sus­pend­ed fund

6 years ago
People
Financing
First page Previous page 921922923924925926927 Next page Last page
A service from the Financial Times